Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trialParesh Dandona, Bertrand Cariou, Diethelm Tschöpe et al.|The Lancet Diabetes & Endocrinology|2017Cited by 295
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 DiabetesRajiv Agarwal, Anantharaman Vathsala, Wanzhu Tu et al.|Annals of Internal Medicine|2023Cited by 94
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD StudyJanusz Gumprecht, Ellen Burgess, Rajiv Agarwal et al.|Diabetes Care|2022Cited by 36